AZ, MZ, and the Pulmonary System Response to Hypoxia

Learn more about:
Related Clinical Trial
Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude. Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance Iron Status and Cardiopulmonary Physiology Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude The Psychophysiological Effect of Simulated and Terrestrial Altitude Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude AZ, MZ, and the Pulmonary System Response to Hypoxia Study of the Effects of Iron Levels on the Lungs at High Altitude Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort Three New Ideas to Protect Special Forces From the Stress of High Altitude Breathing Training to Improve Human Performance at High Altitude Oxidative Stress in Hypobaric Hypoxia Safety Evaluation of Aminophylline and Methazolamide Decompression Tables for Diving at Altitude Chronic Mountain Sickness, Systemic Vascular Function Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Inhaled Budesonide for Altitude Illness Prevention Sickness Evaluation at Altitude With Acetazolamide at Relative Doses Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE) Drug Combination on Exercise Performance at High Altitude Acclimatization Mechanisms During Ascent to 7500m Prevention of Acute Mountain Sickness by Intermittent Hypoxia Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID) Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Training in Hypoxia to Prevent Acute Mountain Sickness Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness Inhaled Budesonide and Acute Mountain Sickness Altitude Sickness Prevention and Efficacy of Comparative Treatments Alternative Treatments in Acute Mountain Sickness Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Brief Title

AZ, MZ, and the Pulmonary System Response to Hypoxia

Official Title

The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Hypoxia

Brief Summary

      The purpose of this proposal is to compare the physiological effects of acetazolamide (AZ)
      and methazolamide (MZ) on the control of breathing and hypoxic pulmonary vasoconstriction.
      The first objective is to assess the effects of AZ and MZ on the control of breathing in
      normoxia and hypoxia. To achieve this the ventilatory interaction between oxygen and carbon
      dioxide will be measured and effects compared between placebo, AZ, and MZ conditions. In
      addition, the isocapnic and poikilocapnic hypoxic ventilatory response and hypercapnic
      ventilatory response will be measured with each drug. The second objective is to assess the
      effects of AZ and MZ on the control of the pulmonary vasculature during hypoxia. Pulmonary
      pressure and cardiac output will be measured during 60 minutes of poikilocapnic hypoxia.
    


Study Phase

Phase 4

Study Type

Interventional


Primary Outcome

Change in ventilation

Secondary Outcome

 Change in cerebral blood velocity

Condition

Altitude Sickness

Intervention

Acetazolamide

Study Arms / Comparison Groups

 Acetazolamide
Description:  Participants will be dosed 250mg Acetazolamide (p.o.) three times per day for two days prior to and a single dose on the day of study.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

14

Start Date

May 2016

Completion Date

August 2016

Primary Completion Date

August 2016

Eligibility Criteria

        Inclusion Criteria:

          -  18-40 years of age

          -  regularly physically active

          -  male

        Exclusion Criteria:

          -  ex-smokers

          -  pulmonary function <80% of predicted

          -  contraindications to carbonic anhydrase inhibitors (eg. severe or absolute glaucoma,
             adrenocortical insufficiency, hepatic insufficiency, renal insufficiency, sulfa
             allergy or an electrolyte imbalance such as hyperchloremic acidosis)

          -  Obese (BMI>30Kg/m2)

          -  diuretic medication use

          -  blood thinner use

          -  anti-platelet drug use.
      

Gender

Male

Ages

18 Years - 40 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Glen E Foster, Ph.D., , 

Location Countries

Canada

Location Countries

Canada

Administrative Informations


NCT ID

NCT02760121

Organization ID

H16-00028


Responsible Party

Sponsor

Study Sponsor

University of British Columbia


Study Sponsor

Glen E Foster, Ph.D., Principal Investigator, University of British Columbia


Verification Date

October 2016